AstraZeneca’s ‘extensive’ obesity drug push; $125M for ultrasound-aided genetic medicine

BioPharma Dive

Newly published data convinced AstraZeneca to conduct a sprawling late-stage program for its GLP-1 pill.

pharminent June 10, 2026 (Last updated: June 10, 2026)

BioPharma Dive

Newly published data convinced AstraZeneca to conduct a sprawling late-stage program for its GLP-1 pill.

Related Stories